$22.17
0.29% today
Nasdaq, Sep 25, 07:45 pm CET

Fulgent Genetics Stock price

$22.10
+0.57 2.65% 1M
+5.14 30.31% 6M
+3.63 19.65% YTD
+0.69 3.22% 1Y
-15.99 41.98% 3Y
-17.42 44.08% 5Y
+12.92 140.74% 10Y
+12.92 140.74% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.16 0.73%

Key metrics

Basic
Market capitalization
$676.5m
Enterprise Value
$386.5m
Net debt
positive
Cash
$292.9m
Shares outstanding
30.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.2 | 2.1
EV/Sales
1.3 | 1.2
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
92.9%
Return on Equity
-3.8%
ROCE
-6.4%
ROIC
-7.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$303.2m | $326.5m
EBITDA
$-64.8m | $-24.2m
EBIT
$-72.7m | $-42.2m
Net Income
$-51.0m | $-10.8m
Free Cash Flow
$-60.0m
Growth (TTM | estimate)
Revenue
4.3% | 15.2%
EBITDA
64.7% | 63.4%
EBIT
62.0% | 42.9%
Net Income
68.8% | 74.7%
Free Cash Flow
-610.2%
Margin (TTM | estimate)
Gross
40.0%
EBITDA
-21.4% | -7.4%
EBIT
-24.0%
Net
-16.8% | -3.3%
Free Cash Flow
-19.8%
More
EPS
$-1.7
FCF per Share
$-2.0
Short interest
12.3%
Employees
1k
Rev per Employee
$220.0k
Show more

Is Fulgent Genetics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Fulgent Genetics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Fulgent Genetics forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Fulgent Genetics forecast:

Buy
78%
Hold
22%

Financial data from Fulgent Genetics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
303 303
4% 4%
100%
- Direct Costs 182 182
3% 3%
60%
121 121
7% 7%
40%
- Selling and Administrative Expenses 136 136
5% 5%
45%
- Research and Development Expense 50 50
6% 6%
16%
-65 -65
65% 65%
-21%
- Depreciation and Amortization 7.97 7.97
0% 0%
3%
EBIT (Operating Income) EBIT -73 -73
62% 62%
-24%
Net Profit -51 -51
69% 69%
-17%

In millions USD.

Don't miss a Thing! We will send you all news about Fulgent Genetics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulgent Genetics Stock News

Positive
The Motley Fool
14 days ago
Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Positive
Seeking Alpha
17 days ago
While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics and anatomic pathology are positioned for sustainable double-digit revenue growth driven by innovation, increased insurance coverage, and geographic expansion. Meanwhile, Fulgent's Pharma segment co...
Positive
The Motley Fool
about 2 months ago
Fulgent (FLGT) Q2 Revenue Jumps 16%
More Fulgent Genetics News

Company Profile

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Head office United States
CEO Ming Hsieh
Employees 1,313
Founded 2016
Website www.fulgentgenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today